Advisory Research Inc Supernus Pharmaceuticals, Inc. Transaction History
Advisory Research Inc
- $512 Million
- Q3 2024
A detailed history of Advisory Research Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisory Research Inc holds 17,097 shares of SUPN stock, worth $647,463. This represents 0.1% of its overall portfolio holdings.
Number of Shares
17,097
Previous 16,766
1.97%
Holding current value
$647,463
Previous $448,000
18.97%
% of portfolio
0.1%
Previous 0.09%
Shares
11 transactions
Others Institutions Holding SUPN
# of Institutions
283Shares Held
60.8MCall Options Held
27.7KPut Options Held
11.3K-
Black Rock Inc. New York, NY10.4MShares$394 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.13MShares$232 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.1MShares$193 Million2.64% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$109 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$99.7 Million0.09% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.03B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...